The USP1/UAF1 complex is emerging as a novel target for cancer treatment (reviewed in [1]), and inhibitors of USP1 catalytic activity have been reported to reverse the resistance to platinum-based chemotherapeutic drugs in NSCLC cells [14,15] and to inhibit the growth of leukemic cell lines [27]. This evidence concerns the gene WDR48 and non-small cell lung carcinoma.